Clinicopathological evaluation of pre-operative chemoradiotherapy with S-1 as a treatment for locally advanced oral squamous cell carcinoma
Clinicopathological evaluation of pre-operative chemoradiotherapy with S-1 as a treatment for locally advanced oral squamous cell carcinoma
复制标题
DOI：
10.3892/ol.2016.4411
复制
发表时间：
2016-05-01
期刊：
影响因子：
2.9
通讯作者：
Nakamura, Seiji
中科院分区：
文献类型：
--
作者：
Kawano, Shintaro;Zheng, Yanqun;Nakamura, Seiji
在本研究中，对术前给予S-1化疗并同时给予总剂量为30戈伊的放疗作为局部晚期口腔鳞状细胞癌（OSCC）的治疗进行了临床病理学评价。参与者包括81例OSCC患者，其中29例II期疾病患者，12例III期疾病患者和40例IV期疾病患者。所有患者均接受总剂量为30戈伊的放射治疗，每日2戈伊，每周5次，共3周，同时患者接受剂量为80-120 mg的S-1，每日2次，连续4周。所有病例均在术前放化疗结束后2-6周进行根治性手术。最常见的不良事件是口咽粘膜炎，但这在所有患者中都是短暂的。未观察到重度血液学或非血液学毒性。临床和组织病理学缓解率分别为70.4%和75.3%。术后，6例患者（7.4%）发生局部失效，2例患者（2.5%）发生颈部失效。远处转移7例（8.6%）。5年总生存率、疾病特异性生存率和局部控制率分别为87.7%、89.9%和90.6%。组织病理学反应差的患者局部复发率高于反应良好的患者（P
The administration of pre-operative chemotherapy with S-1 and concurrent radiotherapy at a total dose of 30 Gy was clinicopathologically evaluated as a treatment for locally advanced oral squamous cell carcinoma (OSCC) in the present study. The participants comprised 81 patients with OSCC, consisting of 29 patients with stage II disease, 12 patients with stage III disease and 40 patients with stage IV disease. All patients received a total radiation dose of 30 Gy in daily fractions of 2 Gy, 5 times a week, for 3 weeks, and the patients were concurrently administered S-1 at a dose of 80-120 mg, twice daily, over 4 consecutive weeks. Radical surgery was performed in all cases at 2-6 weeks subsequent to the end of pre-operative chemoradiotherapy. The most common adverse event was oropharyngeal mucositis, but this was transient in all patients. No severe hematological or non-hematological toxicities were observed. The clinical and histopathological response rates were 70.4 and 75.3%, respectively. Post-operatively, local failure developed in 6 patients (7.4%) and neck failure developed in 2 patients (2.5%). Distant metastases were found in 7 patients (8.6%). The overall survival rate, disease-specific survival rate and locoregional control rate at 5 years were 87.7, 89.9 and 90.6%, respectively. Locoregional recurrence occurred more frequently in patients that demonstrated a poor histopathological response compared with patients that demonstrated a good response (P